Pharmacokinetics and Safety of the 100 Mcg Misoprostol Vaginal Insert (MVI 100)

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

WITHDRAWN

Clinical Phase

PHASE2

Study Classification

INTERVENTIONAL

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This study will provide pharmacokinetic data for the MVI 100 (100 mcg) misoprostol vaginal insert when administered to nulliparous women at term gestation requiring cervical ripening and induction of labor.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Misoprostol Vaginal Insert (MVI) 100, 150, 200 mcg for Cervical Ripening and Induction of Labor

NCT00828711

Cervical Ripening Induction of Labor

COMPLETED PHASE2

Pharmacokinetic (PK) Study of the 200 Microgram (mcg) Misoprostol Vaginal Insert (MVI 200) in Women at Term Gestation (The MVI-PK Study)

NCT01283022

Cervical Ripening Induction of Labor

COMPLETED PHASE2

Efficacy & Safety Study Comparing Misoprostol Vaginal Insert (MVI) Versus Dinoprostone Vaginal Insert (DVI) for Reducing Time to Vaginal Delivery

NCT01127581

Reducing Time to Vaginal Delivery Cervical Ripening Induction of Labor

COMPLETED PHASE3

Safety and Efficacy Study of Misoprostol Vaginal Insert for Induction of Labour

NCT00346840

Labor Induction Cervical Ripening

COMPLETED PHASE2

Efficacy and Safety Study of the Misoprostol Vaginal Priming Insert (MVPI) Prior to Hysteroscopy

NCT00925938

Cervical Priming

COMPLETED PHASE2

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

PK study in women requiring cervical ripening.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Cervical Ripening Induction of Labor

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NON_RANDOMIZED

Intervention Model

SINGLE_GROUP

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

1

Group Type EXPERIMENTAL

Misoprostol Vaginal Insert (MVI 100)

Intervention Type DRUG

The MVI 100 is misoprostol 100 mcg, formulated in a sustained release, nonbiodegradeable hydrogel polymer, with a polyester knit retrieval tape; IV oxytocin is permitted ad lib 30 minutes following removal of the MVI assuming no contraindications.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Misoprostol Vaginal Insert (MVI 100)

The MVI 100 is misoprostol 100 mcg, formulated in a sustained release, nonbiodegradeable hydrogel polymer, with a polyester knit retrieval tape; IV oxytocin is permitted ad lib 30 minutes following removal of the MVI assuming no contraindications.

Intervention Type DRUG

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

Cervical ripener

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Pregnant women at ≥36 weeks 0 days inclusive gestation;
* Aged 18 years or older;
* Candidate for pharmacologic induction of labor;
* Singleton pregnancy;
* Baseline modified Bishop score \<4 (see Appendix B);
* Nulliparous (nulliparous is defined as no previous births live or dead after 24 weeks gestation);
* Written informed consent.

Exclusion Criteria

* Women with hemoglobin level \< 11.0 g/dL (confirmed within one week of study drug insertion);
* Women in active labor;
* Presence of uterine or cervical scar or uterine abnormality e.g. bicornate uterus. Biopsies, including cone biopsy of the cervix, are permitted;
* Administration of oxytocin or any cervical ripening or labor inducing agents (including mechanical methods) or a tocolytic drug within 7 days prior to enrollment. Magnesium sulfate is permitted if prescribed as treatment for pre-eclampsia or pregnancy inducted hypertension;
* Severe pre-eclampsia marked by CNS findings, HELLP syndrome, or other end-organ affliction;
* Suspected or confirmed cephalopelvic disproportion and/or fetal malpresentation;
* Diagnosed fetal abnormalities;
* Suspected or confirmed intrauterine growth retardation (less than 10% estimated fetal weight for dates);
* Any evidence of fetal compromise at baseline (e.g., non-reassuring fetal heart rate pattern or meconium staining);
* Receipt of NSAID (including aspirin) within 4 hours of study treatment;
* Ruptured membranes ≥48 hours prior to the start of treatment or suspected chorioamnionitis;
* Fever (oral or aural temperature \> 37.5C);
* Any condition in which vaginal delivery is contraindicated e.g., placenta previa or any unexplained genital bleeding at any time after 24 weeks during this pregnancy;
* Known or suspected allergy to misoprostol, dinoprostone, other prostaglandins or any of the excipients;
* Any condition urgently requiring delivery;
* Unable to comply with the protocol.

Minimum Eligible Age

18 Years

Eligible Sex

FEMALE

Accepts Healthy Volunteers

Yes